세계 폐동맥 고혈압 시장 : 산업규모, 점유율, 동향, 기회 및 예측(2018년-2028년) - 약제 클래스별, 유형별, 투여경로별, 지역별 및 경쟁별

Pulmonary Arterial Hypertension Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drug Class, By Type, By Route of Administration, By Region, Competition

US $ 4,500 ￦ 6,197,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 7,574,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 11,017,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

세계 폐동맥 고혈압(PAH) 시장은 2022년 66억 6,000만 달러의 평가액에 이르렀고, 예측기간을 통해 대폭적인 성장이 예상됩니다. 복합 연간 성장률(CAGR)은 5.32%로 성장을 지속하여 2028년에는 90억 6,000만 달러에 달할 것으로 예상됩니다.

폐동맥 고혈압은 심장에서 폐로 혈액을 운반하는 폐동맥의 혈압 상승을 특징으로 하는 드물지만 심각한 병리입니다. 이 상태는 폐동맥의 협착과 경화를 일으켜 심장 부담을 증가시키고 심부전을 일으킬 수 있습니다.

세계 폐동맥 고혈압(PAH) 시장은 PAH를 관리하고 다루기 위해 고안된 다양한 의약품, 의료기기 및 치료 전략을 포함하고 있습니다. 의학적 이해, 혁신적인 치료법, PAH에 대한 의식 증가 등 최근 시장 개척이 이 시장의 성장 촉진요인이 되고 있습니다. 이 성장 요인으로는 앉기 쉬운 라이프 스타일과 비만과 같은 위험 요인으로 인한 PAH 유병률 증가, 진단 능력 향상, 환자와 의료 전문가 모두의 의식 증가가 있습니다.

약물 요법은 PAH 관리에 매우 중요한 역할을 하며, PAH 발병과 관련된 특정 경로를 표적으로 하는 약물이 사용되고 있습니다. prostacyclin analogs, endothelin receptor antagonists, phosphodiesterase type 5 inhibitors 등의 이러한 약제는 혈관을 확장하고, 동맥압을 낮추고, 피로와 호흡 곤란 등의 증상을 완화시키는 것을 목적으로 합니다.

시장 개요
예측 기간	2024-2028
시장 규모	66억 6,000만 달러
2028년 시장 규모	90억 6,000만 달러
복합 연간 성장률(CAGR) 2023-2028	5.32%
급성장 부문	phosphodiesterase type 5 inhibitors
최대 시장	북미

또한 폐 혈관 확장 펌프와 같은 의료기기와 보조 인공 심장과 같은 임베디드 기기는 PAH의 중증 사례 관리에 기여합니다. 전통적인 치료와 병행하여, 환자의 QOL을 향상시키기 위해 생활 습관의 개선과 정기적 인 운동이 권장됩니다. 그러나 높은 치료 비용과 전문 의료에 대한 접근 제한 등 PAH 시장에는 과제가 남아 있습니다. 게다가 PAH 진단의 복잡성과 전문 지식의 필요성은 적시의 개입을 방해할 수 있습니다.

주요 시장 성장 촉진요인

• 1. PAH 유병률 증가 및 인지도 향상: PAH 유병률 증가 및 중증도에 대한 인지도 향상은 PAH 시장 확대를 뒷받침하고 있습니다. 공중 보건 캠페인, 의학 교육 개선, 환자 지원 활동은 조기 진단과 조기 개입에 기여합니다.
• 2. 혁신적인 치료 접근법: PAH의 근본적인 메커니즘을 표적으로 한 의약품의 진보는 치료 상황을 변화시켰습니다. 혁신적인 약물과 의료기기는 환자의 결과와 삶의 질을 향상시킵니다.
• 3. 맞춤형 의료: 개별 환자프로파일에 맞는 의료 동향은 중요한 경향입니다. 유전자 검사, 분자 프로파일링, 표적 요법은 치료 효과와 환자 참여를 최적화합니다.

주요 시장 과제

• 1. 높은 치료 비용: PAH 치료제, 의료기기, 전문적인 치료에 드는 비용은 환자와 건강 관리 시스템에 경제적 과제가 됩니다. 효과적인 치료 및 종합적 인 치료에 대한 액세스가 손상 될 수 있습니다.
• 2. 낮은 인지도 : 환자와 의료 종사자의 인식 부족은 진단 지연, 최적의 치료 및 제한된 연구 비용으로 이어집니다. 교육과 광고 활동을 통해 인지도를 높이는 것이 중요합니다.
• 3. 주요 의약품의 특허 만료: 특허의 만료는 치료 접근, 합리적인 가격, 혁신에 영향을 미칩니다. 환자가 합리적인 가격으로 치료를 받을 수 있도록 하는 것과 의약품의 기술 혁신의 균형을 잡는 것이 필수적.

주요 시장 동향

• 1. 공동 조사 및 세계 네트워크: 국제적인 파트너십과 네트워크는 지식 교환, 학제간 접근법, 혁신적인 치료법 및 치료 가이드라인 개발의 가속화를 촉진합니다.
• 2. 개인화 치료 접근법: 유전학 및 분자 프로파일에 기초한 맞춤형 의료는 PAH 치료에 변화를 가져오고 있습니다. 정확한 진단과 표적 치료는 치료 효과와 환자의 강화를 향상시킵니다.

부문별 인사이트

• 1. 약물 클래스별 인사이트: sildenafil과 tadalafil과 같은 phosphodiesterase type 5 inhibitors 억제제는 폐혈관을 이완시키고 증상을 완화시키는 작용이 있기 때문에 PAH 시장을 독점하고 있습니다.
• 2. 유형의 인사이트: 효능과 안전성이 확립된 상표 약은 generics 의약품이 유효하더라도 PAH 치료의 주요 선택권으로 계속되고 있습니다.

지역별 인사이트

북미가 PAH 시장을 선도하는 것은 고급 의료 인프라, 강력한 연구 Initiative 및 규제 당국의 지원 때문입니다. 이 지역에서는 의료 기관 간의 협력, 계발 캠페인 및 환자 지원 활동이 질병 관리 및 결과 개선에 기여합니다.

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 목소리

제5장 폐동맥 고혈압 세계 시장 전망

• 시장 규모 및 예측
  • 금액별
• 시장 점유율 및 예측
  • 약물 클래스별(Prostacyclin 및 Prostacyclin Analogs, 칼슘 채널 차단제, phosphodiesterase type 5 inhibitors, endothelin receptor antagonists, 기타)
  • 유형별(브랜드, generics)
  • 투여 경로별(경구, 정맥내 및 피하, 흡입)
  • 기업별(2022년)
  • 지역별
• 시장 맵

제6장 북미 폐동맥 고혈압 시장 전망

• 시장 규모 및 예측
  • 금액별
• 시장 점유율 및 예측
  • 약제 클래스별
  • 유형별
  • 투여 경로별
  • 국가별
• 북미별 분석
  • 미국
  • 멕시코
  • 캐나다

제7장 유럽 폐동맥 고혈압 시장 전망

• 시장 규모 및 예측
  • 금액별
• 시장 점유율 및 예측
  • 약제 클래스별
  • 유형별
  • 투여 경로별
  • 국가별
• 유럽 국가별 분석
  • 프랑스
  • 독일
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양 폐동맥 고혈압 시장 전망

• 시장 규모 및 예측
  • 금액별
• 시장 점유율 및 예측
  • 약제 클래스별
  • 유형별
  • 투여 경로별
  • 국가별
• 아시아태평양 국가별 분석
  • 중국
  • 인도
  • 한국
  • 일본
  • 호주

제9장 남미 폐동맥 고혈압 시장 전망

• 시장 규모 및 예측
  • 금액별
• 시장 점유율 및 예측
  • 약제 클래스별
  • 유형별
  • 투여 경로별
  • 국가별
• 남미 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카 폐동맥 고혈압 시장 전망

• 시장 규모 및 예측
  • 금액별
• 시장 점유율 및 예측
  • 약제 클래스별
  • 유형별
  • 투여 경로별
  • 국가별
• MEA 국가별 분석
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 최근 동향
• 제품 출시
• 합병 및 인수

제13장 PESTLE 분석

제14장 Porter's Five Forces 분석

• 업계 내 경쟁
• 신규 진입의 가능성
• 공급자의 힘
• 고객의 힘
• 대체품의 위협

제15장 경쟁 구도

• Business Overview
• Company Snapshot
• Product & Services
• Financials(In case of listed companies)
• Recent Developments
• SWOT Analysis
  • Gilead Sciences, Inc.
  • Viatris Inc.
  • Sandoz Inc.(Novartis)
  • Johnson & Johnson
  • Sun Pharmaceutical Industries, Inc.
  • Lupin Pharmaceuticals, Inc.
  • GlaxoSmithKline LLC
  • Johnson & Johnson
  • Bayer AG
  • United Therapeutics Corporation

제16장 전략적 제안

BJH

영문 목차

영문목차

The Global Pulmonary Arterial Hypertension (PAH) Market reached a valuation of USD 6.66 Billion in 2022 and is expected to experience substantial growth throughout the forecast period, projecting a Compound Annual Growth Rate (CAGR) of 5.32% and expected to reach USD 9.06 Billion through 2028. Pulmonary Arterial Hypertension is a rare but serious medical condition characterized by elevated blood pressure in the pulmonary arteries, which carry blood from the heart to the lungs. This condition leads to the narrowing and stiffening of these arteries, placing increased strain on the heart and potentially resulting in heart failure.

The Global Pulmonary Arterial Hypertension (PAH) Market encompasses various pharmaceuticals, medical devices, and treatment strategies designed to manage and address PAH. Recent developments in medical understanding, innovative therapies, and heightened awareness of PAH have been key drivers of growth in this market. Factors contributing to this growth include the increasing prevalence of PAH due to risk factors like sedentary lifestyles and obesity, as well as improved diagnostic capabilities and heightened awareness among both patients and healthcare professionals.

Pharmaceutical interventions play a pivotal role in managing PAH, with drugs targeting specific pathways associated with the disease's pathogenesis. These medications, such as prostacyclin analogs, endothelin receptor antagonists, and phosphodiesterase type 5 inhibitors, aim to dilate blood vessels, reduce arterial pressure, and alleviate symptoms like fatigue and shortness of breath.

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD 6.66 Billion
Market Size 2028	USD 9.06 Billion
CAGR 2023-2028	5.32%
Fastest Growing Segment	Phosphodiesterase 5
Largest Market	North America

Moreover, medical devices like pulmonary vasodilator pumps and implantable devices like ventricular assist devices contribute to managing severe cases of PAH. Alongside conventional therapies, lifestyle modifications and regular exercise are recommended to enhance patients' quality of life. However, challenges persist within the PAH market, including the high cost of treatment and limited access to specialized care. Additionally, the complexity of PAH diagnosis and the need for specialized expertise can hinder timely intervention.

The outlook of the market is characterized by ongoing research and development efforts focused on discovering novel therapies and improving treatment outcomes. Emerging trends such as personalized medicine approaches, biomarker identification, and combination therapies show promise in tailoring treatments to individual patient needs.

In conclusion, the Global Pulmonary Arterial Hypertension (PAH) Market is undergoing significant transformation due to innovative therapies and medical advancements. As awareness of the condition increases and research continues, the market is poised to witness further developments in diagnostics, treatment options, and patient care, ultimately leading to improved outcomes for those affected by this challenging medical condition.

Key Market Drivers

• 1. Increasing Prevalence and Awareness of PAH: The rising prevalence of PAH and growing awareness of its severity have driven the expansion of the PAH Market. Public health campaigns, improved medical education, and patient advocacy initiatives have contributed to early diagnosis and intervention.

• 2. Innovative Therapeutic Approaches: Pharmaceutical advancements targeting PAH's underlying mechanisms have transformed the treatment landscape. Innovative drugs and medical devices are improving patient outcomes and quality of life.

• 3. Personalized Medicine: Tailoring medical care to individual patient profiles is a significant trend. Genetic testing, molecular profiling, and targeted therapies optimize treatment efficacy and patient engagement.

Key Market Challenges

• 1. High Treatment Costs: The cost of PAH medications, medical devices, and specialized care poses financial challenges for patients and healthcare systems. Access to effective treatments and comprehensive care can be compromised.

• 2. Limited Awareness: Lack of awareness among patients and healthcare professionals leads to delayed diagnosis, suboptimal care, and limited research funding. Raising awareness through education and advocacy is crucial.

• 3. Patent Expiration of Key Drugs: Patent expiration affects treatment accessibility, affordability, and innovation. Balancing patients' access to affordable treatments with pharmaceutical innovation is essential.

Key Market Trends

• 1. Collaborative Research and Global Networks: International partnerships and networks facilitate knowledge exchange, interdisciplinary approaches, and accelerated development of innovative therapies and treatment guidelines.

• 2. Personalized Treatment Approaches: Personalized medicine, driven by genetics and molecular profiles, is transforming PAH care. Precise diagnostics and targeted therapies enhance treatment efficacy and patient empowerment.

Segmental Insights

• 1. Drug Class Insights: Phosphodiesterase 5 inhibitors, such as sildenafil and tadalafil, dominate the PAH Market due to their ability to relax pulmonary blood vessels and alleviate symptoms.

• 2. Type Insights: Branded medications, with established efficacy and safety records, continue to be the primary choice in PAH treatment, despite the availability of generics.

Regional Insights

North America leads the PAH Market due to advanced healthcare infrastructure, robust research initiatives, and regulatory support. Collaborations among medical institutions, awareness campaigns, and patient advocacy efforts contribute to improved disease management and outcomes in the region.

Key Market Players

• Gilead Sciences, Inc.
• Viatris Inc.
• Sandoz Inc. (Novartis)
• Johnson & Johnson
• Sun Pharmaceutical Industries, Inc.
• Lupin Pharmaceuticals, Inc.
• GlaxoSmithKline LLC
• Johnson & Johnson
• Bayer AG
• United Therapeutics Corporation

Report Scope:

In this report, the Global Pulmonary Arterial Hypertension Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below.

Pulmonary Arterial Hypertension Market, By Drug Class:

• Prostacyclin and Prostacyclin Analogs
• Calcium Channel Blockers
• Phosphodiesterase 5
• Endothelin Receptor Antagonist
• Others

Pulmonary Arterial Hypertension Market, By Type:

• Branded
• Generics

Pulmonary Arterial Hypertension Market, By Route Of Administration:

• Oral
• Intravenous/ Subcutaneous
• Inhalational

Global Pulmonary Arterial Hypertension Market, By region:

• North America
• United States
• Canada
• Mexico
• Asia-Pacific
• China
• India
• South Korea
• Australia
• Japan
• Europe
• Germany
• France
• United Kingdom
• Spain
• Italy
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Pulmonary Arterial Hypertension Market.

Available Customizations:

• Global Pulmonary Arterial Hypertension Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customers

5. Global Pulmonary Arterial Hypertension Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class (Prostacyclin and Prostacyclin Analogs, Calcium Channel Blockers, Phosphodiesterase 5, Endothelin Receptor Antagonist and Others)
  • 5.2.2. By Type (Branded, Generics)
  • 5.2.3. By Route Of Administration (Oral, Intravenous/ Subcutaneous, Inhalational)
  • 5.2.4. By Company (2022)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Pulmonary Arterial Hypertension Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class
  • 6.2.2. By Type
  • 6.2.3. By Route Of Administration
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Pulmonary Arterial Hypertension Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Type
      • 6.3.1.2.3. By Route Of Administration
  • 6.3.2. Mexico Pulmonary Arterial Hypertension Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Type
      • 6.3.2.2.3. By Route Of Administration
  • 6.3.3. Canada Pulmonary Arterial Hypertension Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Type
      • 6.3.3.2.3. By Route Of Administration

7. Europe Pulmonary Arterial Hypertension Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Type
  • 7.2.3. By Route Of Administration
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Pulmonary Arterial Hypertension Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Type
      • 7.3.1.2.3. By Route Of Administration
  • 7.3.2. Germany Pulmonary Arterial Hypertension Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Type
      • 7.3.2.2.3. By Route Of Administration
  • 7.3.3. United Kingdom Pulmonary Arterial Hypertension Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Type
      • 7.3.3.2.3. By Route Of Administration
  • 7.3.4. Italy Pulmonary Arterial Hypertension Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Class
      • 7.3.4.2.2. By Type
      • 7.3.4.2.3. By Route Of Administration
  • 7.3.5. Spain Pulmonary Arterial Hypertension Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Class
      • 7.3.5.2.2. By Type
      • 7.3.5.2.3. By Route Of Administration

8. Asia-Pacific Pulmonary Arterial Hypertension Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Type
  • 8.2.3. By Route Of Administration
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Pulmonary Arterial Hypertension Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Type
      • 8.3.1.2.3. By Route Of Administration
  • 8.3.2. India Pulmonary Arterial Hypertension Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Type
      • 8.3.2.2.3. By Route Of Administration
  • 8.3.3. South Korea Pulmonary Arterial Hypertension Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Type
      • 8.3.3.2.3. By Route Of Administration
  • 8.3.4. Japan Pulmonary Arterial Hypertension Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Class
      • 8.3.4.2.2. By Type
      • 8.3.4.2.3. By Route Of Administration
  • 8.3.5. Australia Pulmonary Arterial Hypertension Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Class
      • 8.3.5.2.2. By Type
      • 8.3.5.2.3. By Route Of Administration

9. South America Pulmonary Arterial Hypertension Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Type
  • 9.2.3. By Route Of Administration
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Pulmonary Arterial Hypertension Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Type
      • 9.3.1.2.3. By Route Of Administration
  • 9.3.2. Argentina Pulmonary Arterial Hypertension Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Type
      • 9.3.2.2.3. By Route Of Administration
  • 9.3.3. Colombia Pulmonary Arterial Hypertension Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Type
      • 9.3.3.2.3. By Route Of Administration

10. Middle East and Africa Pulmonary Arterial Hypertension Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class
  • 10.2.2. By Type
  • 10.2.3. By Route Of Administration
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Pulmonary Arterial Hypertension Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Class
      • 10.3.1.2.2. By Type
      • 10.3.1.2.3. By Route Of Administration
  • 10.3.2. Saudi Arabia Pulmonary Arterial Hypertension Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Class
      • 10.3.2.2.2. By Type
      • 10.3.2.2.3. By Route Of Administration
  • 10.3.3. UAE Pulmonary Arterial Hypertension Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Class
      • 10.3.3.2.2. By Type
      • 10.3.3.2.3. By Route Of Administration

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Business Overview
• 15.2. Company Snapshot
• 15.3. Product & Services
• 15.4. Financials (In case of listed companies)
• 15.5. Recent Developments
• 15.6. SWOT Analysis
  • 15.6.1. Gilead Sciences, Inc.
  • 15.6.2. Viatris Inc.
  • 15.6.3. Sandoz Inc. (Novartis)
  • 15.6.4. Johnson & Johnson
  • 15.6.5. Sun Pharmaceutical Industries, Inc.
  • 15.6.6. Lupin Pharmaceuticals, Inc.
  • 15.6.7. GlaxoSmithKline LLC
  • 15.6.8. Johnson & Johnson
  • 15.6.9. Bayer AG
  • 15.6.10. United Therapeutics Corporation

16. Strategic Recommendations

관련자료